Efpeglenatide clinical trials
Also written HM11260C.
How each study uses efpeglenatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the efpeglenatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Hypoglycemic Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test efpeglenatide, phase 3 first.
- Nov 2027A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinPhase 3 · Hanmi Pharmaceutical Company Limited
Studies
Open first, then newest update. How each study uses efpeglenatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and DapagliflozinRecruitingPhase 3Hanmi Pharmaceutical Company LimitedNCT07379333Written as HM11260C
- A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes MellitusCompletedPhase 3Hanmi Pharmaceutical Company LimitedNCT06174779Written as HM11260C
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and ExerciseCompletedPhase 3Hanmi Pharmaceutical Company LimitedNCT03353350Written as efpeglenatide (SAR439977)
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)TerminatedPhase 3SanofiNCT03713684Written as Efpeglenatide SAR439977
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With SulfonylureaTerminatedPhase 3SanofiNCT03770728Written as Efpeglenatide SAR439977
- Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminTerminatedPhase 3SanofiNCT03684642Written as Efpeglenatide
- Effect of Efpeglenatide on Cardiovascular OutcomesTerminatedPhase 3SanofiNCT03496298Written as Efpeglenatide (SAR439977)
- Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT02057172Written as HM11260C
- Effect of LAPS-Exendin on Body Weight in Obese PopulationCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT02075281Written as HM11260C
- Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT02081118Written as HM11260C
- Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT01452451Written as HM11260C
- A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes MellitusStatus unknownPhase 1Hanmi Pharmaceutical Company LimitedNCT02059564Written as HM11260C
- A Study of HM11260C in Healthy Male SubjectCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT01093729Written as HM11260C
Codes
What other systems call efpeglenatide · ClinicalTrials.gg INT001379
- MeSH (NLM) C000709212efpeglenatideOne source NLM
- UNII (FDA) 3M1V5Z2270EFPEGLENATIDEConfirmed FDA, NLM
- NCI Thesaurus C166682EfpeglenatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000709212 | efpeglenatide | One source NLM |
| UNII (FDA) | 3M1V5Z2270 | EFPEGLENATIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C166682 | Efpeglenatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.